Secondary Logo

Journal Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

Which patients should receive the herpes zoster vaccine?

Short, Mandy D. PharmD, BPCS, BCGP; Fergus, Christina PharmD, BCPS, CDE

Journal of the American Academy of PAs: September 2019 - Volume 32 - Issue 9 - p 18–20
doi: 10.1097/01.JAA.0000578788.69674.2b
Pharmacology Consult
Buy

ABSTRACT The recombinant adjuvanted zoster vaccine (RZV, trade name Shingrix) is preferentially recommended by the Advisory Committee on Immunization Practices to prevent herpes zoster and related complications in immunocompetent adults age 50 years and older. This article reviews efficacy and safety of the vaccine, its use in special populations, and how to prevent administration errors to answer the question “Which patients should receive the herpes zoster vaccine?”

Mandy D. Short and Christina Fergus are pharmacists at Blue Cross Blue Shield of Arizona. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2019 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website